Atara Biotherapeutics Announces Proposed Offering of Common Stock
February 27, 2018 16:01 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Progress
February 27, 2018 07:00 ET
|
Atara Biotherapeutics, Inc.
– Initiated two Phase 3 clinical studies to evaluate tab-cel™ (tabelecleucel) in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder (EBV+ PTLD) who have failed...
Atara Biotherapeutics Announces Chief Financial Officer Intention to Retire in April 2018
February 21, 2018 16:06 ET
|
Atara Biotherapeutics, Inc.
Launches Search for Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy...
Atara Biotherapeutics Announces FDA Clearance to Proceed with Enrollment at U.S. Sites for Ongoing Global Phase 1 Clinical Study to Evaluate ATA188 in Patients with Progressive or Relapsing-Remitting Multiple Sclerosis
January 10, 2018 08:00 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
January 04, 2018 16:15 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 04, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics Announces Pricing of Public Offering of Common Stock
January 03, 2018 22:55 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics Announces Proposed Offering of Common Stock
January 02, 2018 16:01 ET
|
Atara Biotherapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for...
Atara Biotherapeutics Announces Initiation of Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
January 02, 2018 08:00 ET
|
Atara Biotherapeutics, Inc.
– Three clinical sites for both the MATCH and ALLELE pivotal studies now open for enrollment in the U.S. – SOUTH SAN FRANCISCO, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc....
Atara Biotherapeutics Announces FDA Clearance to Initiate Two Phase 3 Clinical Studies to Evaluate Tabelecleucel in Patients with Rituximab-Refractory Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder (EBV+PTLD)
December 29, 2017 06:00 ET
|
Atara Biotherapeutics, Inc.
– Pivotal studies to commence imminently – – Primary endpoint results and EU conditional marketing authorization submission expected in the first half of 2019 – – Company to host conference call and...
Atara Biotherapeutics to Host Corporate Update Conference Call on Friday, December 29, 2017, at 8:00 a.m. EST
December 28, 2017 18:30 ET
|
Atara Biotherapeutics, Inc.
– Company to announce FDA clearance to initiate two Phase 3 tabelecleucel clinical studies – SOUTH SAN FRANCISCO, Calif., Dec. 28, 2017 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc....